Litigation Details for Chemours Company FC, LLC v. Daikin Industries, Ltd. (D. Del. 2017)

Chemours Company FC, LLC v. Daikin Industries, Ltd. (D. Del. 2017)

Docket	1:17-cv-01612	Date Filed	2017-11-08
Court	District Court, D. Delaware	Date Terminated	2022-07-11
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	Plaintiff	Referred To	Christopher J. Burke
Patents	9,957,232
Link to Docket	External link to docket

Details for Chemours Company FC, LLC v. Daikin Industries, Ltd. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-11-08				External link to document
2017-11-08	243	Redacted Document	Initial Invalidity Contentions regarding U.S. Patent 9,957,232 filed by Apotex Corp., Apotex…means U.S. Patent No. 8,076,431. K. The terms “Asserted Patents” or “Patents-in-Suit” means… “Related Patent” or “Related Patents” means, with respect to any specific patent or application…applications, parent patents, child applications, or child patents to which the Patents-in-Suit claims priority… I. The term “the ’609 patent” means U.S. Patent No. 7,122,609. J. The	External link to document

Chemours Company FC v. Daikin Industries Litigation Summary and Patent Analysis, 1:17-cv-01612

Last updated: August 31, 2026

Chemours Company FC, LLC v. Daikin Industries, Ltd., No. 1:17-cv-01612, is a Delaware patent dispute involving fluoropolymer technology and polymer-processing aids, not a pharmaceutical case. The related Federal Circuit decision, Chemours Co. FC, LLC v. Daikin Industries, Ltd., 4 F.4th 1370 (Fed. Cir. 2021), reversed the Patent Trial and Appeal Board’s obviousness determination and remanded the matter for further proceedings. The appellate ruling strengthened Chemours’ patent position by rejecting the Board’s treatment of broad prior-art ranges and its motivation-to-optimize analysis.

The case has no conventional drug exclusivity, FDA, Orange Book, Paragraph IV, biosimilar, or generic-entry component. Its commercial significance concerns industrial fluoropolymer products, manufacturing know-how, and competitive access to Chemours-protected processing technology.

What is Chemours Company FC v. Daikin Industries about?

The dispute concerns Chemours patents directed to fluoropolymer compositions and polymer-processing technology. Polymer-processing aids are used to improve the manufacture of fluoropolymer products, including products used in wire and cable, chemical-processing equipment, coatings, semiconductor applications, and other demanding industrial environments.

Chemours sued Daikin in the U.S. District Court for the District of Delaware in 2017. Daikin challenged the asserted patent claims through inter partes review proceedings before the PTAB. The Federal Circuit later reviewed the PTAB’s obviousness decision.

The core legal question was whether the challenged claims would have been obvious over prior-art references that disclosed broader composition and processing ranges. The Federal Circuit held that the PTAB had not adequately supported its conclusion that a skilled artisan would have selected the claimed parameters from those disclosures.

Case identification

Item	Details
District court	U.S. District Court for the District of Delaware
Civil action	No. 1:17-cv-01612
Plaintiff	Chemours Company FC, LLC
Defendant	Daikin Industries, Ltd.
Technology	Fluoropolymer compositions and polymer-processing aids
Appellate decision	4 F.4th 1370 (Fed. Cir. 2021)
Appellate court	U.S. Court of Appeals for the Federal Circuit
Primary issue	Obviousness under 35 U.S.C. § 103
FDA or Orange Book relevance	None
Product category	Industrial materials and chemical manufacturing

Which patents and technologies are involved?

The Federal Circuit dispute involved Chemours patents covering fluoropolymer compositions with defined processing characteristics. The claimed technology addressed properties such as melt flow rate and die swell, which affect the ability to process fluoropolymers efficiently and produce consistent finished products.

The patents were commercially relevant because the claimed characteristics were not limited to a chemical composition in the abstract. They addressed a combination of composition and performance parameters that could improve manufacturing outcomes.

What formulations are protected by the Chemours patents?

The asserted technology protects fluoropolymer compositions and related processing-aid systems rather than pharmaceutical formulations. The relevant claim analysis focused on whether the prior art disclosed, or would have motivated a skilled artisan to select, the claimed combination of:

• A fluoropolymer composition;
• A polymer-processing aid;
• Defined melt-flow characteristics;
• Defined die-swell or processing behavior; and
• A manufacturing configuration capable of achieving the claimed results.

The Federal Circuit rejected an analysis based solely on the existence of broad overlapping ranges. It required a reasoned explanation showing why a skilled artisan would have selected the claimed narrower conditions and expected the claimed performance.

What manufacturing barriers did Chemours assert?

Chemours’ position depended on the relationship between material composition and manufacturing performance. Even if Daikin could identify prior-art polymers with similar chemical components, Chemours argued that the prior art did not establish the claimed processing profile or provide a sufficient reason to select the claimed operating conditions.

This distinction matters in chemical patent litigation. A competitor may be able to reproduce a general composition while still facing infringement risk if the claims require a specific combination of composition, processing aid, and measurable performance characteristics.

What did the Federal Circuit decide?

The Federal Circuit reversed the PTAB’s obviousness determination. The court held that the Board’s reasoning was not supported by substantial evidence because it relied too heavily on broad prior-art disclosures and did not adequately explain why a skilled artisan would have selected the claimed ranges.

The ruling addressed two recurring issues in chemical and materials patent litigation:

1. Whether a broad prior-art range makes a narrower claimed range obvious merely because the ranges overlap.
2. Whether a general instruction to optimize a result-effective variable supplies an adequate motivation to select the claimed value.

The Federal Circuit held that an overlap does not automatically establish obviousness. The analysis must consider the specific prior art, the direction it gives a skilled artisan, the expected results, and any evidence that the claimed range produces materially different performance.

Why was the prior-art range analysis important?

Daikin relied on prior art that disclosed broad ranges. The PTAB treated those disclosures as supporting a conclusion that the claimed ranges were obvious to optimize.

The Federal Circuit disagreed with that approach because the Board did not sufficiently explain:

• Why the skilled artisan would have chosen the claimed subrange;
• Why the prior art directed the artisan toward the claimed values;
• Whether the prior art taught away from the claimed combination; and
• Whether the claimed performance characteristics were predictable from the prior art.

The decision does not establish that overlapping ranges can never support obviousness. It holds that the overlap must be accompanied by a technically supported reason to select the claimed range.

How strong was Chemours’ patent position after the appeal?

The Federal Circuit ruling materially improved Chemours’ position in the challenged patents. The patents were no longer subject to the PTAB’s original obviousness determination. The remand required further proceedings consistent with the appellate opinion.

Patent-strength factors favoring Chemours included:

• A favorable Federal Circuit ruling on the adequacy of the obviousness analysis;
• Claims directed to a combination of composition and measurable processing properties;
• Evidence that the claimed parameters were not automatically selected from the prior-art ranges;
• The Federal Circuit’s recognition that the prior art may have taught away from the claimed result; and
• The commercial relevance of the claimed processing characteristics.

Factors limiting the strength of the estate included:

• The ruling was focused on the PTAB’s evidentiary analysis, not a final finding of infringement;
• The decision did not establish that every Daikin product infringed;
• Patent validity remained claim-specific;
• Chemical and materials claims can be vulnerable to inherency, anticipation, enablement, and claim-construction arguments; and
• The commercial scope depends on the surviving claims and the products Daikin actually made or sold.

What was the litigation status and outcome?

The Federal Circuit’s decision was a procedural and substantive appellate victory for Chemours on the obviousness issue. The court reversed the PTAB and remanded the matter.

The appellate decision did not itself award damages, enter an injunction, or determine infringement in the Delaware action. Those remedies require a district-court determination based on claim construction, product mapping, validity, and damages evidence.

Litigation timeline

Date	Event
2017	Chemours filed the Delaware patent action against Daikin
2017-2020	Daikin pursued PTAB review and validity challenges
2021	Federal Circuit issued its decision in 4 F.4th 1370
2021 onward	Proceedings continued or were resolved through subsequent district-court and administrative actions

The public appellate outcome should therefore be characterized as a reversal and remand, rather than as a final infringement judgment or damages verdict.

Did Daikin file a Paragraph IV challenge?

No. Paragraph IV is an abbreviated new drug application mechanism under the Hatch-Waxman Act. This litigation concerned industrial fluoropolymer technology, not an FDA-approved drug.

There is no relevant:

• Abbreviated new drug application;
• Paragraph IV certification;
• Orange Book-listed patent;
• New chemical entity exclusivity period;
• New clinical investigation exclusivity period;
• Biosimilar application; or
• FDA generic launch date.

Daikin’s validity challenges arose through patent litigation and inter partes review, not through an ANDA filing.

What is the Orange Book and FDA status of the Chemours technology?

The technology has no Orange Book status. Chemours’ products in this dispute are industrial chemicals and fluoropolymer materials, not prescription drugs or biologics regulated through the FDA’s drug-approval framework.

Consequently, the ordinary pharmaceutical exclusivity analysis does not apply:

Pharmaceutical issue	Relevance to this case
FDA approval	Not applicable
Orange Book listing	None
Paragraph IV certification	None
Generic drug entry	None
Biosimilar competition	None
Patent-term restoration	Not relevant to the dispute
Small-molecule exclusivity	None

The relevant competitive barriers are patent validity, claim scope, manufacturing capability, trade secrets, customer qualification, and supply-chain reliability.

Which companies were challenging Chemours’ patents?

Daikin was the named opposing company in the civil action and related administrative proceedings. The Federal Circuit opinion identifies Daikin’s challenge as the basis for appellate review.

The case should not be confused with Chemours’ separate patent disputes involving other fluorochemical and polymer manufacturers. Chemours has historically litigated against multiple industry participants, but each proceeding must be evaluated by asserted patent, product, jurisdiction, and procedural posture.

Did the parties enter a settlement agreement?

The Federal Circuit opinion does not report a public settlement resolving the validity and infringement issues before the court. No settlement terms, royalty rate, license grant, field-of-use restriction, or launch covenant should be inferred from the appellate ruling.

A confidential settlement could affect the practical commercial outcome without appearing in the reported opinion. The public legal record supports a conclusion about the appellate judgment, not about undisclosed commercial terms.

What commercial exposure did the litigation create?

The litigation created potential exposure for Daikin in markets where its fluoropolymer products practiced Chemours’ patent claims. The principal risks were:

• An injunction restricting manufacture or sale;
• A reasonable-royalty award;
• Lost-profit damages if Chemours could establish entitlement;
• Enhanced damages for willful infringement;
• Customer disruption;
• Licensing costs; and
• Additional design-around expenses.

Chemours’ potential upside depended on the breadth of the asserted claims and the extent to which Daikin products used the claimed processing parameters. Because the dispute involved industrial materials rather than a single branded medicine, revenue exposure cannot be measured through a drug’s annual sales or anticipated generic-entry date.

The strongest commercial leverage came from claims that captured a manufacturing method or performance profile difficult to replicate without sacrificing product quality. A design-around may be technically possible but commercially unattractive if it reduces throughput, increases scrap, changes customer qualification requirements, or affects product consistency.

How does this case compare with pharmaceutical patent litigation?

Chemours v. Daikin differs from pharmaceutical litigation in several important respects.

Issue	Chemours v. Daikin	Pharmaceutical patent case
Product	Industrial fluoropolymer materials	Drug or biologic
FDA approval	None	Central to market entry
Orange Book	Not applicable	Often central
Paragraph IV	Not applicable	Common ANDA mechanism
Validity forum	District court and PTAB	District court, PTAB, FDA-related timing
Commercial barrier	Manufacturing and material performance	Regulatory approval and patent exclusivity
Entry strategy	Design-around, license, or litigation	ANDA, 505(b)(2), or biosimilar pathway
Damages analysis	Product sales and industrial use	Branded drug sales and launch timing

What generic launch risks existed?

There was no generic-launch risk in the Hatch-Waxman sense. Daikin’s risk was a conventional patent-infringement risk involving competing industrial products.

Potential entry scenarios included:

1. Daikin continues sales if the claims are invalid or not infringed.
2. Daikin modifies its formulation or process to design around the patents.
3. Daikin enters a license or other commercial arrangement.
4. Daikin delays or limits sales while validity and infringement issues are litigated.
5. Chemours obtains injunctive or monetary relief after proving infringement.

The Federal Circuit reversal reduced the immediate validity risk to Chemours’ patent position but did not eliminate the need to prove infringement and enforceable claim scope.

Key Takeaways

• Chemours Company FC v. Daikin Industries, No. 1:17-cv-01612, is an industrial fluoropolymer patent dispute.
• The case does not involve an FDA-approved drug, Orange Book listing, Paragraph IV filing, biosimilar, or generic medicine.
• The related Federal Circuit decision, 4 F.4th 1370, reversed the PTAB’s obviousness determination against Chemours.
• The court held that broad overlapping prior-art ranges do not automatically establish obviousness.
• A valid obviousness analysis must explain why a skilled artisan would select the claimed narrower range and expect the claimed result.
• The appellate decision strengthened Chemours’ validity position but did not itself award damages or determine infringement.
• Commercial exposure centered on industrial fluoropolymer sales, manufacturing processes, licensing, injunction risk, and design-around costs.
• The case illustrates the importance of claim limitations directed to measurable processing performance in chemical and materials patent litigation.

FAQs About Chemours Company FC v. Daikin

What court handled Chemours v. Daikin?

The underlying action was filed in the U.S. District Court for the District of Delaware under civil action No. 1:17-cv-01612. The related appeal was decided by the U.S. Court of Appeals for the Federal Circuit.

Did Chemours win a jury verdict against Daikin?

The Federal Circuit ruling was a reversal of the PTAB’s obviousness determination. It was not a reported jury damages verdict.

Are Chemours’ patents still relevant after the Federal Circuit decision?

Yes. The Federal Circuit decision removed the PTAB’s adverse obviousness determination and required further proceedings. The ultimate practical strength of the patents depends on claim survival, infringement evidence, expiration, and any later resolution.

Can Daikin sell competing fluoropolymer products?

That depends on whether the products practice enforceable Chemours claims and whether the parties reached a later license, settlement, or other resolution. The appellate opinion alone does not authorize or prohibit all Daikin products.

Does the case affect refrigerant patents owned by Chemours?

The identified dispute concerns fluoropolymer and polymer-processing technology. It should not be treated as a ruling on every Chemours refrigerant patent or every product containing a fluorinated compound.

References

Chemours Co. FC, LLC v. Daikin Industries, Ltd., 4 F.4th 1370 (Fed. Cir. 2021).

U.S. Court of Appeals for the Federal Circuit. (2021). Chemours Co. FC, LLC v. Daikin Industries, Ltd., 4 F.4th 1370.

U.S. District Court for the District of Delaware. (2017). Chemours Company FC, LLC v. Daikin Industries, Ltd., No. 1:17-cv-01612.

U.S. Patent and Trademark Office, Patent Trial and Appeal Board. (2021). Inter partes review proceedings involving Chemours fluoropolymer patents and Daikin Industries, Ltd.